Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development » 09:08
02/01/23
02/01
09:08
02/01/23
09:08
IONS

Ionis Pharmaceuticals

$39.87 /

+0.625 (+1.59%)

, GSK

GSK

$35.27 /

+0.155 (+0.44%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals (IONS) announced that GSK (GSK) has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen, an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection. Ionis earned a $15M milestone payment from GSK associated with the progression of bepirovirsen into the Phase 3 clinical studies.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.87 /

+0.625 (+1.59%)

GSK GSK
$35.27 /

+0.155 (+0.44%)

IONS Ionis Pharmaceuticals
$39.87 /

+0.625 (+1.59%)

01/19/23 Piper Sandler
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
12/21/22 Guggenheim
Ionis 2023 revenue estimate raised at Guggenheim
12/21/22 Morgan Stanley
Ionis assumed with Equal Weight from Overweight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
GSK GSK
$35.27 /

+0.155 (+0.44%)

01/30/23 JMP Securities
JMP Securities says older-adult update continues to look encouraging for CureVac
01/18/23 SVB Securities
Moderna price target raised to $111 from $102 at SVB Securities
01/09/23 Jefferies
CureVac upgraded to Buy at Jefferies after mRNA platform validation
01/08/23 BofA
CureVac 'likely too late for COVID upside,' says BofA
IONS Ionis Pharmaceuticals
$39.87 /

+0.625 (+1.59%)

GSK GSK
$35.27 /

+0.155 (+0.44%)

GSK GSK
$35.27 /

+0.155 (+0.44%)

GSK GSK
$35.27 /

+0.155 (+0.44%)

GSK GSK
$35.27 /

+0.155 (+0.44%)

Tuesday
Hot Stocks
Ionis Pharmaceuticals receives FDA Fast Track designation for olezarsen » 07:06
01/31/23
01/31
07:06
01/31/23
07:06
IONS

Ionis Pharmaceuticals

$39.24 /

-0.77 (-1.92%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals announced that the U.S. FDA has granted olezarsen Fast Track designation for the treatment of familial chylomicronemia syndrome. Ionis fully enrolled its global Phase 3 BALANCE study of olezarsen in adult patients with FCS last year. The company plans to share data from the BALANCE study in the second half of 2023.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.24 /

-0.77 (-1.92%)

IONS Ionis Pharmaceuticals
$39.24 /

-0.77 (-1.92%)

01/19/23 Piper Sandler
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
12/21/22 Guggenheim
Ionis 2023 revenue estimate raised at Guggenheim
12/21/22 Morgan Stanley
Ionis assumed with Equal Weight from Overweight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
IONS Ionis Pharmaceuticals
$39.24 /

-0.77 (-1.92%)

Monday
Recommendations
Azek price target raised to $24 from $18 at Loop Capital » 09:14
01/30/23
01/30
09:14
01/30/23
09:14
AZEK

Azek

$23.95 /

+0.79 (+3.41%)

Loop Capital analyst…

Loop Capital analyst Jeffrey Stevenson raised the firm's price target on Azek to $24 from $18 but keeps a Hold rating on the shares as part of a broader research note on Building Products. The firm's quarterly composite decking survey reported a number of improving industry dynamics being offset by a slowing demand environment, the analyst tells investors in a research note, stating that while channel destocking was completed at the end of the December quarter, 2023 sales expectations also declined for the majority of respondents compared with 90 days ago. The worst is likely behind for decking names after a challenging 2022 however, even though half of the contacts in the survey do not have backlogs beyond Q1, Loop Capital added.

ShowHide Related Items >><<
AZEK Azek
$23.95 /

+0.79 (+3.41%)

AZEK Azek
$23.95 /

+0.79 (+3.41%)

01/30/23 BofA
Azek downgraded to Neutral at BofA following outperformance
01/30/23 BofA
Azek downgraded to Neutral from Buy at BofA
01/10/23 Deutsche Bank
Azek price target raised to $28 from $24 at Deutsche Bank
01/10/23 Deutsche Bank
Deutsche shuffles ratings in repair and remodel sector, upgrades Pool
AZEK Azek
$23.95 /

+0.79 (+3.41%)

AZEK Azek
$23.95 /

+0.79 (+3.41%)

Downgrade
Azek downgraded to Neutral at BofA following outperformance » 06:56
01/30/23
01/30
06:56
01/30/23
06:56
AZEK

Azek

$23.95 /

+0.79 (+3.41%)

As previously reported,…

As previously reported, BofA analyst Rafe Jadrosich downgraded Azek to Neutral from Buy with a price target of $25, up from $20. Shares have increased 32% since the company reported fiscal Q3 results on November 28, noted the firm, which notes that FY23 earnings guidance already implies record EBITDA margins in the second half. The firm also expects destocking to continue through calendar Q1 and noted that its channel checks with decking distributors indicate some competitor discounts have been extended into 2023.

ShowHide Related Items >><<
AZEK Azek
$23.95 /

+0.79 (+3.41%)

AZEK Azek
$23.95 /

+0.79 (+3.41%)

01/30/23 BofA
Azek downgraded to Neutral from Buy at BofA
01/10/23 Deutsche Bank
Azek price target raised to $28 from $24 at Deutsche Bank
01/10/23 Deutsche Bank
Deutsche shuffles ratings in repair and remodel sector, upgrades Pool
01/10/23 Citi
Azek downgraded to Neutral from Buy at Citi
AZEK Azek
$23.95 /

+0.79 (+3.41%)

AZEK Azek
$23.95 /

+0.79 (+3.41%)

Downgrade
Azek downgraded to Neutral from Buy at BofA » 06:04
01/30/23
01/30
06:04
01/30/23
06:04
AZEK

Azek

$23.95 /

+0.79 (+3.41%)

BofA analyst Rafe…

BofA analyst Rafe Jadrosich downgraded Azek to Neutral from Buy.

ShowHide Related Items >><<
AZEK Azek
$23.95 /

+0.79 (+3.41%)

AZEK Azek
$23.95 /

+0.79 (+3.41%)

01/10/23 Deutsche Bank
Azek price target raised to $28 from $24 at Deutsche Bank
01/10/23 Deutsche Bank
Deutsche shuffles ratings in repair and remodel sector, upgrades Pool
01/10/23 Citi
Azek downgraded to Neutral from Buy at Citi
01/05/23 UBS
UBS downgrades Azek on 'optimistic' 2023 financial expectations
AZEK Azek
$23.95 /

+0.79 (+3.41%)

AZEK Azek
$23.95 /

+0.79 (+3.41%)

Over a week ago
Hot Stocks
Ionis confirms FDA to hold advisory committee meeting on tofersen NDA » 11:53
01/23/23
01/23
11:53
01/23/23
11:53
IONS

Ionis Pharmaceuticals

$40.19 /

-0.5 (-1.23%)

, BIIB

Biogen

$289.39 /

+3.68 (+1.29%)

Ionis (IONS) issued the…

Ionis (IONS) issued the following statement about the FDA advisory committee meeting on tofersen: "On Jan. 23, the Federal Register published a notice that the U.S. Food and Drug Administration will convene a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to review data supporting the New Drug Application for tofersen, an investigational medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis - SOD1-ALS. The advisory committee meeting is scheduled for March 22, 2023. SOD1-ALS is an ultra-rare genetic form of ALS that affects approximately 330 people in the U.S.1 It is progressive, leads to the loss of everyday functions and is uniformly fatal. The NDA for tofersen has a Prescription Drug User Fee Act action date of April 25, 2023. Additional details about the advisory committee meeting can be found in a separate statement by Biogen which is available on their website." Reference Link

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$40.19 /

-0.5 (-1.23%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

IONS Ionis Pharmaceuticals
$40.19 /

-0.5 (-1.23%)

01/19/23 Piper Sandler
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
12/21/22 Guggenheim
Ionis 2023 revenue estimate raised at Guggenheim
12/21/22 Morgan Stanley
Ionis assumed with Equal Weight from Overweight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
BIIB Biogen
$289.39 /

+3.68 (+1.29%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
IONS Ionis Pharmaceuticals
$40.19 /

-0.5 (-1.23%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

Recommendations
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler » 10:46
01/19/23
01/19
10:46
01/19/23
10:46
IONS

Ionis Pharmaceuticals

$40.17 /

+0.38 (+0.96%)

Piper Sandler analyst Do…

Piper Sandler analyst Do Kim raised the firm's price target on Ionis Pharmaceuticals to $62 from $60 and keeps an Overweight rating on the shares. Eplontersen, the company's investigational medicine to treat transthyretin amyloidosis, continues to be a key driver of share value, Kim tells investors. FDA acceptance of eplontersen is expected in Q1. The company is expected to reveal data from the drug's NEURO study in mid-2023 and this should be a catalyst, the analyst said. Kim adds olezarsen should be Ionis' next commercial product and Phase 3 data is expected in the second half of this year.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$40.17 /

+0.38 (+0.96%)

IONS Ionis Pharmaceuticals
$40.17 /

+0.38 (+0.96%)

12/21/22 Guggenheim
Ionis 2023 revenue estimate raised at Guggenheim
12/21/22 Morgan Stanley
Ionis assumed with Equal Weight from Overweight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
11/10/22 Citi
Ionis Pharmaceuticals price target raised to $31 from $28 at Citi
IONS Ionis Pharmaceuticals
$40.17 /

+0.38 (+0.96%)

Recommendations
Azek price target raised to $28 from $24 at Deutsche Bank » 16:30
01/10/23
01/10
16:30
01/10/23
16:30
AZEK

Azek

$22.97 /

+0.25 (+1.10%)

Deutsche Bank analyst Joe…

Deutsche Bank analyst Joe Ahlersmeyer raised the firm's price target on Azek (AZEK) to $28 from $24 and keeps a Buy rating on the shares. Within the repair and remodel sector, the analyst believes low-ticket products and projects could soften in the near term as excess savings "evaporate," impacting demand. He believes inflation's effect on the end consumer will ultimately weaken manufacturer pricing power across channels as well. This view, along with valuation considerations, drives his downgrade of Fortune Brands Innovations (FBHS) to Hold from Buy and Masco (MAS) to Sell from Hold. On the other hand, high-ticket remodeling may "counterintuitively" hold up better as locked-in homeowners, largely secure in post-pandemic home equity gains, look to make improvements that can improve the eventual selling price of their home, Ahlersmeyer tells investors in a research note.

ShowHide Related Items >><<
AZEK Azek
$22.97 /

+0.25 (+1.10%)

AZEK Azek
$22.97 /

+0.25 (+1.10%)

01/10/23 Deutsche Bank
Deutsche shuffles ratings in repair and remodel sector, upgrades Pool
01/10/23 Citi
Azek downgraded to Neutral from Buy at Citi
01/05/23 UBS
UBS downgrades Azek on 'optimistic' 2023 financial expectations
01/05/23 UBS
Azek downgraded to Neutral from Buy at UBS
AZEK Azek
$22.97 /

+0.25 (+1.10%)

AZEK Azek
$22.97 /

+0.25 (+1.10%)

Recommendations
Deutsche shuffles ratings in repair and remodel sector, upgrades Pool » 16:29
01/10/23
01/10
16:29
01/10/23
16:29
FBIN

Fortune Brands Innovations

$61.23 /

+0.06 (+0.10%)

, MAS

Masco

$50.80 /

+0.45 (+0.89%)

, TREX

Trex Company

$48.17 /

+1.48 (+3.17%)

, AZEK

Azek

$22.97 /

+0.25 (+1.10%)

, BECN

Beacon

$52.31 /

-0.55 (-1.04%)

, PGTI

PGT Innovations

$18.64 /

+0.135 (+0.73%)

, POOL

Pool Corp.

$324.90 /

+7.12 (+2.24%)

Within the repair and…

Within the repair and remodel sector, Deutsche Bank analyst Joe Ahlersmeyer believes low-ticket products and projects could soften in the near term as excess savings "evaporate," impacting demand. He believes inflation's effect on the end consumer will ultimately weaken manufacturer pricing power across channels as well. This view, along with valuation considerations, drives his downgrade of Fortune Brands Innovations (FBHS) to Hold from Buy and Masco (MAS) to Sell from Hold. On the other hand, high-ticket remodeling may "counterintuitively" hold up better as locked-in homeowners, largely secure in post-pandemic home equity gains, look to make improvements that can improve the eventual selling price of their home, Ahlersmeyer tells investors in a research note. In keeping with this theme, Ahlersmeyer maintains Buy ratings on Trex Company (TREX), Azek (AZEK), Beacon (BECN) and PGT Innovations (PGTI), and he also upgraded Pool Corp. (POOL) to Buy from Hold.

ShowHide Related Items >><<
TREX Trex Company
$48.17 /

+1.48 (+3.17%)

POOL Pool Corp.
$324.90 /

+7.12 (+2.24%)

PGTI PGT Innovations
$18.64 /

+0.135 (+0.73%)

MAS Masco
$50.80 /

+0.45 (+0.89%)

FBIN Fortune Brands Innovations
$61.23 /

+0.06 (+0.10%)

BECN Beacon
$52.31 /

-0.55 (-1.04%)

AZEK Azek
$22.97 /

+0.25 (+1.10%)

FBIN Fortune Brands Innovations
$61.23 /

+0.06 (+0.10%)

01/10/23 Deutsche Bank
Fortune Brands Innovations downgraded to Hold from Buy at Deutsche Bank
12/23/22 Baird
Fortune Brands Innovations price target raised to $64 from $59.82 at Baird
12/19/22 Deutsche Bank
Fortune Brands Innovations removed from 'Top Picks' at Deutsche Bank
12/16/22 Zelman
Fortune Brands Innovations initiated with a Hold at Zelman
MAS Masco
$50.80 /

+0.45 (+0.89%)

01/10/23 Deutsche Bank
Masco downgraded to Sell from Hold at Deutsche Bank
12/14/22 Barclays
Masco price target raised to $61 from $58 at Barclays
10/27/22 BMO Capital
Masco price target lowered to $55 from $60 at BMO Capital
10/27/22 Truist
Masco price target lowered to $60 from $70 at Truist
TREX Trex Company
$48.17 /

+1.48 (+3.17%)

12/14/22 Barclays
Trex Company price target lowered to $51 from $53 at Barclays
11/29/22 Barclays
Azek price target lowered to $23 from $27 at Barclays
11/02/22 BMO Capital
Trex Company price target lowered to $58 from $65 at BMO Capital
11/01/22 Stifel
Trex Company price target lowered to $60 from $68 at Stifel
AZEK Azek
$22.97 /

+0.25 (+1.10%)

01/10/23 Citi
Azek downgraded to Neutral from Buy at Citi
01/05/23 UBS
UBS downgrades Azek on 'optimistic' 2023 financial expectations
01/05/23 UBS
Azek downgraded to Neutral from Buy at UBS
12/14/22 Barclays
Azek price target raised to $28 from $23 at Barclays
BECN Beacon
$52.31 /

-0.55 (-1.04%)

12/19/22 Stifel
Beacon price target raised to $91 from $80 at Stifel
10/20/22 Deutsche Bank
Beacon price target lowered to $79 from $90 at Deutsche Bank
10/14/22 Baird
Beacon downgraded to Neutral at Baird as survey points to competitive pricing
10/14/22 Baird
Beacon downgraded to Neutral from Outperform at Baird
PGTI PGT Innovations
$18.64 /

+0.135 (+0.73%)

10/20/22 Deutsche Bank
PGT Innovations price target lowered to $29 from $38 at Deutsche Bank
08/17/22 Deutsche Bank
Armstrong World, Trex among Deutsche Bank's top building products picks
08/17/22 Deutsche Bank
PGT Innovations initiated with a Buy at Deutsche Bank
07/15/22 JPMorgan
PGT Innovations price target lowered to $19 from $22 at JPMorgan
POOL Pool Corp.
$324.90 /

+7.12 (+2.24%)

01/10/23 Deutsche Bank
Pool Corp. upgraded to Buy from Hold at Deutsche Bank
12/15/22 BofA
BofA starts Pool Corp. with an Underperform on weaker pool demand
12/15/22 BofA
Pool Corp. initiated with an Underperform at BofA
10/24/22 Deutsche Bank
Pool Corp. price target lowered to $350 from $368 at Deutsche Bank
TREX Trex Company
$48.17 /

+1.48 (+3.17%)

POOL Pool Corp.
$324.90 /

+7.12 (+2.24%)

PGTI PGT Innovations
$18.64 /

+0.135 (+0.73%)

MAS Masco
$50.80 /

+0.45 (+0.89%)

BECN Beacon
$52.31 /

-0.55 (-1.04%)

AZEK Azek
$22.97 /

+0.25 (+1.10%)

POOL Pool Corp.
$324.90 /

+7.12 (+2.24%)

TREX Trex Company
$48.17 /

+1.48 (+3.17%)

POOL Pool Corp.
$324.90 /

+7.12 (+2.24%)

MAS Masco
$50.80 /

+0.45 (+0.89%)

BECN Beacon
$52.31 /

-0.55 (-1.04%)

AZEK Azek
$22.97 /

+0.25 (+1.10%)

FBIN Fortune Brands Innovations
$61.23 /

+0.06 (+0.10%)

Downgrade
Azek downgraded to Neutral from Buy at Citi » 06:27
01/10/23
01/10
06:27
01/10/23
06:27
AZEK

Azek

$22.72 /

+0.54 (+2.43%)

Citi analyst Anthony…

Citi analyst Anthony Pettinari downgraded Azek to Neutral from Buy with a price target of $23, up from $21. The downgrade reflects expectations for discretionary weakness in 2023 and an updated view on the stock's valuation, Pettinari tells investors in a research note. The analyst thinks Azek has become more fairly valued on a relative basis.

ShowHide Related Items >><<
AZEK Azek
$22.72 /

+0.54 (+2.43%)

AZEK Azek
$22.72 /

+0.54 (+2.43%)

01/05/23 UBS
UBS downgrades Azek on 'optimistic' 2023 financial expectations
01/05/23 UBS
Azek downgraded to Neutral from Buy at UBS
12/14/22 Barclays
Azek price target raised to $28 from $23 at Barclays
11/30/22 B. Riley
Azek price target lowered to $25 from $26 at B. Riley
AZEK Azek
$22.72 /

+0.54 (+2.43%)

AZEK Azek
$22.72 /

+0.54 (+2.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.